FDA label 3d491d8b-7fa0-47e4-bec0-4fe6d944fa25

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
8c174b11-a061-412e-a3b2-7bf7e1adaace
SPL ID
3d491d8b-7fa0-47e4-bec0-4fe6d944fa25
Version
12
Effective date
2025-03-17
Source export date
2026-11-13
Source partition
7
Source file
https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:35:49

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: THROMBOSIS Thrombosis may occur with immune globulin products, including XEMBIFY. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. [ see Warnings and Precautions (5.2) , Patient Counseling Information (17) ] For patients at risk of thrombosis, administer XEMBIFY at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Warnings and Precautions (5.2) ] WARNING: THROMBOSIS See full prescribing information for complete boxed warning. Thrombosis may occur with immune globulin products, including XEMBIFY. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. For patients at risk of thrombosis, administer XEMBIFY at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Aseptic Meningitis Syndrome (AMS) occurs within two days of treatment. ( 5.1 ) Hypersensitivity and anaphylactic reactions may occur. IgA deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity or anaphylactic reactions. ( 5.3 ) Monitor for renal function in patients at risk for renal failure. ( 5.4 ) Hemolysis can develop. Risk factors include high doses and non-O blood group. Closely monitor for hemolysis and hemolytic anemia. ( 5.5 ) Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). ( 5.6 ) XEMBIFY is made from human plasma and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.7 ) Passive transfer of antibodies may confound serologic testing. ( 5.8 ) 5.1 Aseptic Meningitis Syndrome Aseptic meningitis syndrome (AMS) has been reported with the use of human immune globulin administered intravenously and subcutaneously, including XEMBIFY. AMS usually begins within several hours to 2 days following immune globulin treatment. AMS may occur more frequently in females than in males. AMS is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea and vomiting. Cerebrospinal fluid (CSF) studies frequently show pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dL, but negative culture results. To rule out other causes of meningitis, conduct a thorough neurological examination on patients exhibiting such symptoms and signs, including CSF studies. AMS may occur more frequently in association with high doses ( > 2 g/kg) and/or rapid infusion of immune globulin products. Discontinuation of immune globulin treatment has resulted in remission of AMS within several days without sequelae. 5.2 Thrombosis Thrombosis may occur following treatment with immune globulin products, including XEMBIFY. 5-7 Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer XEMBIFY at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Boxed Warning , Dosage and Administration (2.3) , Patient Counseling Information (17) ] 5.3 Hypersensitivity Severe hypersensitivity reactions may occur with human immune globulin products, including XEMBIFY. If a hypersensitivity reaction occurs, discontinue the XEMBIFY infusion immediately and institute appropriate treatment. XEMBIFY contains IgA. Patients with known anti-IgA antibodies have a greater risk of developing potentially severe hypersensitivity reactions, including anaphylaxis. XEMBIFY is contraindicated in IgA deficient patients with antibodies against IgA and history of hypersensitivity to human immune globulin treatment. [see Contraindications (4) ] 5.4 Renal Dysfunction/Failure Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis and death may occur upon use of human immune globulin products, especially those containing sucrose. 8,9 XEMBIFY does not contain sucrose. Ensure that patients are not volume depleted prior to administration of XEMBIFY. In patients with any degree of preexisting renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, age greater than 65 years, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs), monitor renal function and consider lower, more frequent dosing. [see Dosage and Administration (2.3) ] Periodic monitoring of renal function and urine output is particularly important in patients judged to have a potential increased risk for developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN)/serum creatinine, prior to the initial infusion of XEMBIFY and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation of XEMBIFY . [see Patient Counseling Information (17) ] 5.5 Hemolysis IgG products, including XEMBIFY can contain blood group antibodies that may act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin (Coombs’) test result and hemolysis. 10-13 Delayed hemolytic anemia can develop subsequent to human immune globulin therapy due to enhanced RBC sequestration, and acute hemolysis consistent with intravascular hemolysis has been reported. [see Adverse Reactions (6) ] Monitor XEMBIFY recipients for clinical signs and symptoms of hemolysis, particularly patients with risk factors such as non-O blood group, or patients receiving high IgG doses (≥ 2 grams/kg). 14 Underlying inflammatory state in an individual patient may increase the risk of hemolysis, but its role is uncertain. 15 If signs and/or symptoms of hemolysis are present after XEMBIFY infusion, perform appropriate confirmatory laboratory testing. 5.6 Transfusion-Related Acute Lung Injury Noncardiogenic pulmonary edema (transfusion-related acute lung injury [TRALI]) may occur in patients following treatment with human immune globulin products. 16 TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Symptoms typically occur within 1 to 6 hours after treatment. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support. 5.7 Transmissible Infectious Agents Because XEMBIFY is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. No cases of transmission of viral diseases or CJD have been associated with the use of XEMBIFY. ALL infections suspected by a physician to have possibly been transmitted by XEMBIFY should be reported by the physician or other healthcare provider to Grifols Therapeutics LLC [1-800-520-2807]. 5.8 Interference with Laboratory Tests After infusion with XEMBIFY, the transitory rise of various passively transferred antibodies in the patient’s blood may yield false-positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions in ≥ 5% of patients in the clinical trial were local adverse reactions including infusion site erythema (redness), infusion site pain, infusion site swelling (puffiness), infusion site bruising, infusion site nodule, infusion site pruritus (itching), infusion site induration (firmness), infusion site scab, infusion site edema, and systemic reactions including cough and diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Grifols Therapeutics LLC at 1-800-520-2807 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in other clinical trials of another drug and may not reflect the rates observed in clinical practice. Study 1 The safety of XEMBIFY was evaluated in an open-label, single-arm prospective multi-center study in North America in patients with PI who received subcutaneous XEMBIFY for at least 6 months [see Clinical Studies (14) ] . A total of 49 patients (including 14 patients between 2 to 16 years of age) received 1053 XEMBIFY infusions during the clinical trial. The average number of infusions per patient was 21.5 infusions, median 24 infusions (range 1-26 infusions). A total of 390 local infusion site reactions occurred at a rate per infusion of 0.370 (approximately 1 in 2.7 infusions). Of these, the most common was infusion site erythema which had a median duration of 24.9 hours. Infusion site swelling, and infusion site pain had median durations of 24.5 and 22.8 hours, respectively. Local infusion site reactions of all kinds by site of infusion (where site of infusion was recorded) occurred in 50.0% and 52.6% of patients during infusions in the abdomen versus thigh, respectively, and across 773 abdominal infusions and 279 thigh infusions rates were 0.184 and 0.735 per infusion, respectively; this corresponds to 1 in 5.4 infusions (for abdomen) and 1 in 1.4 infusions (for thigh). No local infusion site reactions were considered severe or serious. The adverse reactions occurring in ≥ 5% of patients on XEMBIFY in the clinical trial for the duration of the subcutaneous (SC) phase are shown in Table 4 below which includes all treatment-emergent adverse reactions except infections. Table 4: Adverse Reactions in ≥ 5% of Patients During Treatment The term ‘treatment’ refers to the duration of the subcutaneous phase of XEMBIFY administration. with XEMBIFY in Study 1 Adverse Reaction Including all adverse reactions that occurred after the first dose of XEMBIFY regardless of causality, excluding infections. By Patient n (%) Number and percentage of patients with the adverse reaction. (N=49 patients) By Infusion n (rate) Rate per infusion is calculated as the total number of adverse reactions divided by the total number of infusions. (N=1053 infusions) Infusion site erythema 19 (39%) 123 (<1) Infusion site pain 9 (18%) 32 (<1) Infusion site swelling 8 (16%) 124 (<1) Infusion site bruising 8 (16%) 26 (<1) Infusion site nodule 8 (16%) 13 (<1) Infusion site pruritus 5 (10%) 28 (<1) Infusion site induration 4 (8%) 6 (<1) Infusion site scab 3 (6%) 6 (<1) Infusion site edema 3 (6%) 5 (<1) Cough 3 (6%) 4 (<1) Diarrhea 3 (6%) 3 (<1) Four patients discontinued XEMBIFY due to adverse reactions which were infusion site nodules, infusion site discomfort, skin papules/plaques, and arthralgia/myalgia. Study 2 The safety of XEMBIFY during 12 months of treatment was evaluated in 61 patients (including 29 pediatric patients aged 2 to ≤16 years) in a clinical trial in Europe [ see Clinical Studies (14) ]. Adverse reactions in pediatric and adult patients were similar to those observed in Study 1. Among early withdrawals from the study, one patient discontinued XEMBIFY due to a related infusion site fibroma that resolved. Study 3 The safety of XEMBIFY was compared between weekly and biweekly dosing during a single-sequence weekly-to-biweekly crossover study of 27 treatment-experienced adult patients with PI [see Clinical Studies (14) ] . The incidence of adverse reactions was similar between dosing regimens and similar to those observed in Study 1. The safety of XEMBIFY administered to 6 treatment-naïve adults with PI was assessed during a loading dose phase of 5 daily treatments with XEMBIFY followed by a weekly maintenance phase [see Clinical Studies (14) ] . Adverse reactions occurring in more than one patient included infusion site swelling in 2 (33%) patients during or after 13 infusions and infusion site bruising in 2 (33%) patients during or after 2 infusions. 6.2 Postmarketing Experience The following adverse events have been identified during post approval use of XEMBIFY. Because these events are reported voluntarily and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these events or establish a causal relationship to product exposure. Immune system disorders: Anaphylactic reaction and hypersensitivity Nervous system disorders: Aseptic meningitis, dizziness, and paresthesia Cardiovascular disorders: Tachycardia and hypotension Respiratory, thoracic and mediastinal disorders: Dyspnea and chest discomfort General disorders and administration site conditions: Injection site reactions (such as induration and warmth), chills, fatigue, and pain The following adverse events have been identified and reported during the postmarketing use of immune globulin products administered subcutaneously: Nervous system disorders: Tremor Respiratory, thoracic and mediastinal disorders: Laryngospasm

adverse reactions table

<table ID="SPLSERV-05b20f1f-ff87-4998-aebe-f9bcc556e8f8" cellpadding="4" cellspacing="0" styleCode="Noautorules" width="60%"><caption>Table 4: Adverse Reactions in &#x2265; 5% of Patients During Treatment<footnote ID="SPLSERV-BFEFE86D-D5B7-92C7-A00D-1780DF901157">The term &#x2018;treatment&#x2019; refers to the duration of the subcutaneous phase of XEMBIFY administration.</footnote> with XEMBIFY in Study 1</caption><colgroup><col align="left" width="34%"/><col align="center" width="33%"/><col align="center" width="33%"/></colgroup><tbody><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="bottom"><content styleCode="bold">Adverse Reaction<footnote ID="SPLSERV-E0E32FBE-5BF1-EECB-7160-A1F043EA6DEF">Including all adverse reactions that occurred after the first dose of XEMBIFY regardless of causality, excluding infections.</footnote></content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">By Patient </content><content styleCode="bold">n (%)<footnote ID="SPLSERV-89C7E507-6A2C-5973-CF90-360DDE41669A">Number and percentage of patients with the adverse reaction.</footnote> </content><content styleCode="bold">(N=49 patients)</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">By Infusion n (rate)</content><footnote ID="SPLSERV-7B8E6FED-CE5B-6CF4-5D8B-C05BBE53B894">Rate per infusion is calculated as the total number of adverse reactions divided by the total number of infusions.</footnote> <content styleCode="bold">(N=1053 infusions)</content></td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Infusion site erythema </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 19 (39%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">123 (&lt;1)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Infusion site pain </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 9 (18%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">32 (&lt;1)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Infusion site swelling </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 8 (16%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">124 (&lt;1)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Infusion site bruising </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 8 (16%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">26 (&lt;1)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Infusion site nodule </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 8 (16%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">13 (&lt;1)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Infusion site pruritus </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 5 (10%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">28 (&lt;1)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Infusion site induration </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 4 (8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">6 (&lt;1)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Infusion site scab </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 3 (6%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">6 (&lt;1)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Infusion site edema </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 3 (6%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 (&lt;1)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Cough </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 3 (6%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 (&lt;1)</td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Diarrhea </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"> 3 (6%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 (&lt;1)</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.